Comparative Pharmacology
Head-to-head clinical analysis: DIUPRES 500 versus SER A GEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIUPRES 500 versus SER A GEN.
DIUPRES-500 vs SER-A-GEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diupres-500 is a combination of chlorothiazide, a thiazide diuretic, and reserpine, a Rauwolfia alkaloid. Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and increasing water excretion. Reserpine depletes catecholamines from central and peripheral nerve terminals by blocking vesicular monoamine transporter 2 (VMAT2), leading to decreased sympathetic outflow and vasodilation.
SER-A-GEN is a serotonin receptor agonist that selectively activates 5-HT1A and 5-HT2A receptors, modulating neurotransmitter release in the central nervous system.
Oral, 1 tablet (hydrochlorothiazide 50 mg + reserpine 0.125 mg) once daily, increased up to 2 tablets per day if needed.
500 mg orally once daily.
None Documented
None Documented
Reserpine: 50-100 hours (prolonged; clinical effect persists for days due to irreversible MAO depletion). Hydrochlorothiazide: 6-15 hours (biphasic; terminal phase reflects renal elimination).
8 ± 2 hours; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: ~50% (primarily hydrochlorothiazide), Fecal: ~50% (primarily reserpine).
Primarily renal: 70% unchanged drug; 20% as glucuronide conjugate; <5% fecal.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination